Pfizer says its COVID-19 vaccine protection lasts at least six months

METRO PLUS

Many feared dead as explosion rocks Benue community [PHOTOS]

Scores have been reportedly killed in a fuel tanker explosion at the Amoke village of Apa Local Government Area in Benue State.

Osun: One dead, children, others injured as masquerades attack Muslims

At least, one person has been confirmed dead while about 12 persons, including children sustained gunshot injuries in a clash that ensued...

4 confirmed dead after car hit six pedestrians in Yola

Four pedestrians have been confirmed dead and two others injured after a car hit them around the Adamawa State capital, Yola.

Two rescued, 12 abducted in Kaduna community

Kaduna Police Command has rescued two persons, while 12 others were abducted by bandits in Kachia local government area of Kaduna State.

Man sets in-law’s house ablaze in Jigawa

A 40-year-old man, Ibrahim Musa has set his in-law’s house ablaze at Kuzoyara village, Birniwa local Government area of Jigawa State.

Pfizer Inc and BioNTech’s COVID-19 vaccine is around 91% effective at preventing the disease, they said on Thursday, citing updated trial data that included participants inoculated for up to six months.

The shot was also 100% effective in preventing illness among trial participants in South Africa, where a new variant called B1351 is dominant, though the number of those participants was relatively small at 800.

While the new overall efficacy rate of 91.3% is lower than the 95% originally reported in November for its 44,000-person trial, a number of variants have become more prevalent around the world since then.

Pfizer Chief Executive Albert Bourla said the updated results, which include data on more than 12,000 people fully inoculated for at least six months, positions the drugmakers to submit for full U.S. regulatory approval.

The vaccine is currently authorized on an emergency basis by the U.S. Food and Drug Administration.

The trial data “provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population,” BioNTech Chief Executive Ugur Sahin said in a statement.

Experts fear that new variants of COVID-19 from South Africa and Brazil could be resistant to existing vaccines and treatment. More than 300 cases of the South African variant have been detected in more than 25 U.S. states and jurisdictions, federal data shows.

The vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined by the U.S. Food and Drug Administration.

There were also no serious safety concerns observed in trial participants up to six months after the second dose, the companies said.

They added that it was generally equally effective irrespective of age, race, gender or ethnicity and among participants with a variety of existing medical conditions.

“These data reinforce our view that we have some really potent vaccines,” said Danny Altmann, a professor of immunology at Britain’s Imperial College London, who was not involved in the Pfizer trial.

He said the effectiveness against the South African variant was “especially noteworthy,” since it showed the vaccine is likely to offer effective protection in real-world settings where several different coronavirus variants could be circulating.

The trial reviewed more than 900 confirmed cases of COVID-19, most of which were among participants who received a placebo.

The release of updated results comes on the heels of separate data that showed the vaccine is safe and effective in 12 to 15-year-olds, paving the way for the drugmakers to seek U.S. and European approval to use the shot in this age group within weeks.

(Additional reporting by Michael Erman in New York and Kate Kelland in London; editing by Peter Henderson, Edwina Gibbs and David Goodman)

Sources: CTV News

Sign up to FREE email alerts from Tribunepoint Weekly - Daily News

When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.

- Advertisement -

Read Also

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest News

Buhari’s assent to PIB lack of respect for Nigerians – PDP

The Peoples Democratic Party (PDP) has called for the immediate amendment of the new Petroleum Industry Act Bill recently approved by President...

‘He was in good health, great spirits’ – Saraki reacts to death of Ibrahim Mantu

Immediate past President of the Senate, Dr. Abubakar Bukola Saraki, has reacted to the death of Ibrahim Mantu, a former Deputy Senate...

Buhari mourns ex-Deputy Senate President, Ibrahim Mantu

President Muhammadu Buhari has condoled with the family of former Deputy Senate President, Ibrahim Mantu, joining the Plateau State Government and indigenes...

Anambra 2021: Soludo remains APGA Guber candidate – Ex-CBN boss’ spokesman, Pauly Onyeka insists

The camp of former Central Bank of Nigeria, CBN, Governor Prof. Charles Soludo, has rubbished the recent court orders declaring Chuma Umeoji...

Kwara APC crisis: Parallel congresses imminent on Saturday

There are strong indications that parallel congresses will be held by the two major warring factions of the All Progressives Congress in...